Page 21234..1020..»

Researchers develop nanoclay-based bioprinting method to produce functional bone implants – 3D Printing Industry

Using 3D printers, researchers have collaborated from around the globe to develop nanoclay-based 3D bioprinted scaffolds which could be used to aid skeletal regeneration.

Hailing from the University of Southampton, the Istituto Italiano di Tecnologia in Rome, University Hospital Carl Gustav Carus and Technische Universitt in Dresden, and China Medical University in Taiwan, the researchers 3D bioprinted implantable nanocomposite scaffolds, laden with human bone marrow stromal cells (HBMSCs) and human umbilical vein endothelial cells (HUVECs), which have the potential to facilitate bone formation.

3D bioprinting for orthopedics

Ideally, 3D printed implants of this nature should sustain cell viability and promote cells to multiply, in addition to generating functional constructs shortly after printing and stimulating the host microenvironment to aid tissue growth.

Realistically, bioprinting is in its infancy and the prospect of whole 3D printed transplant organs is still probably decades away. However, there have been a number of innovative developments in the field thus far, such asa novel bio-ink enabling scientists at the University of Minnesota to create a functional 3D printed beating human heart.

Similarly, researchers fromTsinghua Universityhave3D bioprinted brain-like tissue structures capable of nurturing neural cells, while in May microdispensing specialistnScryptand aerospace companyTechShotsuccessfully completed the first functional 3D bioprinting experiment in space a human knee meniscus.

Most recently, researchers from theUniversity of Montrealhave developed a new method of cell bioprinting based on a drop-on-demand technique, called Laser Induced Side Transfer, which utilizes a low energy nanosecond laser and the laws of microfluidic dynamics to jet living cells onto each other. The team believes their work could be adapted for applications such as 3D drug screening models and artificial tissues.

The nanoclay-based method

According to the report,nanoclay-based bioink formulations are particularly attractive for implant applications given their ability, even at low concentrations, to shear while being extruded and regain their shape upon deposition, while shielding cells from potential damage from the printing process.

During the study, scientists harnessed the physiochemical properties of Laponite (LAP), a smectite nanoclay suspension, and combined it with HBMSCs, bone morphogenic protein-2 (BMP-2), and vascular endothelial growth factor to produce LAP-alginate-methylcellulose bioink. HBMSCs, collected from patients undergoing routine hip surgery, and HUVECs, obtained from the umbilical cords of healthy mothers after normal, full-term deliveries, were encapsulated in the bioink and printed using an in-house built bioprinter.

After printing, the scaffolds were incubated for 10 minutes in a sterile calcium chloride solution to enable crosslinking.

The skeletal functionality of the HBMSCs-laden 3D bioprinted scaffolds was investigated in vitro, ex vivo, and in vivo. The results demonstrated significant improvements in mineralized tissue formation with the addition of HBMSCs in 3DP, but not in mold-cast bulk scaffolds.

Significance of the findings

According to the researchers, the printing of bioinks laden with cells that can act as building blocks for the generation of tissue-like structures represents a simple and effective approach to produce readily implantable constructs.

The potential to print stem cells, preserving cell viability, proliferation, and functionality, is currently a key unmet challenge for the biofabrication approach to regenerative medicine. Clay-based bioinks, such as the one looked at in this study, are now proven to offer an attractive vehicle for printing HBMSCs in three-dimensional constructs due to their shear-thinning and inherent functional properties.

Further details of the study can be found in the article titledNanoclay-based 3D printed scaffolds promote vascular ingrowth ex vivo and generate bone mineral tissue in vitro and in vivo, published in the Biofabrication journal. The article is co-authored by Gianluca Cidonio, Michael Glinka, Yang-Hee Kim, Janos Kanczler, Stuart Lanham, Tilman Ahlfeld, Anja Lode, Jonathan Dawson, Michael Gelinsky, and Richard Oreffo.

The 4th annual 3D Printing Industry Awards are coming up in November 2020 and we need a trophy. To be in with a chance of winning a brand newCraftbot Flow IDEX XL3D printer,enter the MyMiniFactory trophy design competition here. Were happy to accept submissions until the 30th of September 2020.

Subscribe to the3D Printing Industry newsletterfor the latest news in additive manufacturing. You can also stay connected by following us onTwitterand liking us onFacebook.

Looking for a career in additive manufacturing? Visit3D Printing Jobsfor a selection of roles in the industry.

Featured image shows functional investigation of 3D printed scaffold vascularisation in a CAM model. Image via Biofabrication journal.

See the article here:
Researchers develop nanoclay-based bioprinting method to produce functional bone implants - 3D Printing Industry

Recommendation and review posted by Bethany Smith

Block party planned to raise awareness of sickle cell disease – Greenville Journal

Life expectancy for people with sickle cell disease appears to be declining, and the same systemic racism being protested around the nation could be at least partly responsible, a local expert says.

If you compare other orphan diseases, like cystic fibrosis or hemophilia, which have less cases than sickle cell, and then compare funding and research, its a night-and-day difference, said Dr. Alan R. Anderson, director of Prisma Health Upstates Comprehensive Sickle Cell Disease Program.

The U.S. Food and Drug Administration defines an orphan disease as a condition that affects fewer than 200,000 people nationwide.

That directly goes along with this same prejudice, racial disparities that we see in our political-social landscape, he said. Its about time we recognize this is a serious problem.

Anderson points to a National Institutes of Health study that concluded that life expectancy dropped from 42 for men and 48 for women in the early 1990s to 42 for women and 38 for men in 2005 even as life expectancy increased for people with other chronic conditions.

And a Sept. 1 New England Journal of Medicine article reports that while cystic fibrosis affects a third fewer than sickle cell, it receives seven to 11 times the funding. The authors added that the development of disease-modifying therapies has stagnated because of inadequate research funding, attributable at least in part to structural racism.

Sickle cell disease (SCD) is a genetic disorder of the red blood cells that primarily affects African Americans, though people from Hispanic, southern European, Middle Eastern, southern Asia, or Asian Indian backgrounds can also get the disease. Both parents must carry the genes for their child to get the disease.

While healthy cells are round, in people with SCD they resemble a sickle, or C shape, and are also hard and sticky, clogging the flow of blood through the vessels, according to the U.S. Centers for Disease Control and Prevention. Symptoms include pain, infections and stroke, and typically begin when a child is around 5 months old.

Treatments include medicines that can reduce complications and extend life, the agency reports, but the only cure is a risky bone marrow or stem cell transplant from a close match, like a brother or sister.

The state Department of Health and Environmental Control says that despite improvements in treatments, SCD remains a life-limiting disease with multi-organ complications that reduces the quality of life of impacted individuals especially as the person ages.

DHEC also reports that SCD has suffered from decades of poor disease awareness and lack of funding compared to other inherited disorders.

Historically, Anderson said, while children are cared for via Medicaid, adults often lack insurance so they have no medical home. And along with the funding disparity, there is a lack of training for medical professionals about SCD.

This is not rocket science, he said. If you focus on sickle cell disease like you do on diabetes and other chronic diseases, we will see reductions in acute care needs that will ultimately manifest in life expectancy.

DHEC has an SCD plan that calls for improving access to care, sustainable funding and increasing the educational awareness of medical professionals about SCD.

Its going to take more research and more advocacy and, I believe, policy changes, said the Rev. Sean Dogan of Long Branch Baptist Church in Greenville. We need that same momentum for SCD as well.

Anderson said that Prismas program has stepped up preventive health strategies and treatments for people of all ages while reducing ER visits and hospitalizations by about 50%, which will hopefully increase life expectancy.

Last year, it launched Camp Crescent to provide SCD patients and their families a respite from the disease. But the pandemic prevented that this year.

So organizers are holding a block party from 4-6 p.m. on Sept. 19 where people can safely gather for some fun and to raise awareness, said Dogan.

Its going to be an exciting event to raise awareness [and] celebrate those who have SCD and their caregivers, he said. The more awareness the community has, the more support it will give. And our community is a very generous community.

Modeled on the drive-by birthday parties so popular during the pandemic, it will feature patients and their families driving by the entrance of Prismas Cancer Center on Faris Road, he said. There, theyll find encouragement, well wishes and fun activities like quizzes with prizes, he said.

Meanwhile, on Sunday, blood drives to benefit patients will be held in the area, including one at Long Branch from 10 a.m. to 2 p.m., he said.

To learn more about the event, go to or

While the exact number of people with SCD is unknown, its estimated they number about 100,000 nationwide.

South Carolina doesnt track SCD numbers, but between 1991 and 2017, 1,884 infants were born with it, DHEC said. Another 56,607 were born with sickle cell trait, which means they dont have symptoms but can pass the gene on to their children.

Go here to see the original:
Block party planned to raise awareness of sickle cell disease - Greenville Journal

Recommendation and review posted by Bethany Smith

Silent spreaders of the coronavirus are the target of a new testing venture in San Antonio – San Antonio Express-News

After Graham Weston caught the coronavirus from his son, who hadnt shown any symptoms, the San Antonio tech entrepreneur realized that the role of silent spreaders demanded more attention.

He and other prominent philanthropic leaders in the city formed a new nonprofit with the express purpose of screening hundreds and eventually thousands of people to identify who is infected and asymptomatic and keep them from unknowingly spreading the virus.

The larger goal is even more ambitious: deliver an effective way of supporting societys recovery from the pandemic.

We can never really suppress the virus and give people the confidence to go back (to school or work) when we have silent spreaders walking through our population, said Weston, founder of the 80 | 20 Foundation and former CEO and chairman of Rackspace Technology.

The nonprofit, called Community Labs, has adopted a new approach to testing that focuses on micro populations in shared places, such as area schools and businesses.

It is using an existing test developed by Thermo Fisher Scientific. The polymerase chain reaction, or PCR, test relies on a sample taken from the front of the nostril easier on the person getting tested. Results will be available within 24 hours, far faster than many providers of coronavirus tests, the nonprofits leaders said Thursday during their announcement of the initiative.

The nonprofit will pilot the testing effort in the Somerset Independent School District. It has the capacity to process 600 tests a day and aims to scale up to 12,000 tests a day by November, with the goal of lowering the price to $35 per test.

Community Labs is working with BioBridge Global, which houses the nonprofit and conducts the testing in collaboration with UT Health San Antonio. BioBridge, which operates San Antonios blood bank, owns its own lab off Interstate 10 near Vance Jackson on the West Side.

Experts estimate that up to half of people who contract the coronavirus may display no symptoms, said bank executive J. Bruce Bugg Jr., chairman and trustee of the Tobin Endowment and co-founder of Community Labs. While hospitals have widely screened patients for the coronavirus when they are scheduled for surgery, federal and local health officials have largely prioritized testing people with symptoms.

On New nonprofit aims to improve COVID-19 testing

Its an approach that has persisted since early in the pandemic, when testing for the coronavirus was severely limited by regulatory, processing and supply chain bottlenecks. Health departments, including the San Antonio Metropolitan Health District, initially focused their efforts on people who were severely ill, those with classic symptoms and front-line workers.

Metro Health briefly tested asymptomatic people in the community earlier this year but halted the effort when a surge of cases over the summer caused demand for testing to skyrocket.

While testing those with symptoms may help diagnose people with COVID-19, it does little to halt chains of transmission that stem from asymptomatic carriers. To fill that testing gap, Community Labs is taking the exact opposite approach, Bugg said.

He said the goal is to create a strong testing model that screens for asymptomatic carriers and that can be replicated and applied in cities across the state.

Community Labs approach hinges on quick turnaround times, which are not typical with the traditional testing. Waiting a week for results would render the value of testing asymptomatic people moot, Weston said, as they wont know to isolate themselves and already could have spread the virus to others by the time they learn they are infected.

Dr. Rachel Beddard, chief medical officer of BioBridge, said the company already conducts fast, high-volume testing for communicable diseases on blood products collected by the South Texas Blood and Tissue Center and on tissue, bone marrow and stem cells gathered by GenCure, another subsidiary.

Earlier this year, federal regulators granted an emergency use authorization for the coronavirus test that BioBridge is using.

On San Antonio students are back in classrooms very different classrooms

Somerset ISD, a seven-school system in rural Southwest Bexar County, was selected as a demonstration site after its superintendent, Saul Hinojosa, agreed to participate.

With about 40 percent of all students having returned to school for in-person learning, the district will begin testing students and staff Wednesday, starting with students involved in extracurricular activities, all high school staff and all nurses and police officers. Only students whose parents sign a consent form will be tested at school, Hinojosa said.

The goal is to test as many students as possible so they, their parents and staff feel comfortable returning to school. If everything goes according to plan and enough students agree to get tested, Hinojosa said, the entire district could be back learning face to face earlier than expected.

We need students in the classroom because thats where they learn best, and we hope that this strategy will lessen the concern on parents, along with the anxiety, to where they feel confident that the school campus is a safe environment for the kids, he said.

Unlike the deep nasal swabs that have been used to collect samples for many coronavirus tests, the test used by Community Labs uses a sample thats simpler and far less invasive to collect. Participants rub a small Q-tip inside each nostril for five seconds before dropping it into a test tube.

Community Labs was co-founded by Weston, Bugg and J. Tullos Wells, managing director of the Kronkosky Charitable Foundation. Weston is serving as chairman, while Bugg and Wells are vice chairmen.

The Kronkosky and 80 | 20 foundations and the Tobin Endowment have contributed a combined $2.5 million to start the nonprofit.

Lauren Caruba covers health care and medicine in the San Antonio and Bexar County area. To read more from Lauren, become a subscriber. | Twitter: @LaurenCaruba

The rest is here:
Silent spreaders of the coronavirus are the target of a new testing venture in San Antonio - San Antonio Express-News

Recommendation and review posted by Bethany Smith

The Pandemic Is Chasing Aging Coaches From the Field – The New York Times

After Coach Paul Trosclair won a Louisiana high school football championship in December 2018, he and his family walked from the Superdome in New Orleans to celebrate with a bowl of late-night gumbo. He mused about retiring, but no one took him seriously.

For five seasons, Trosclair had endured fatigue and other effects of multiple myeloma, a treatable but incurable blood cancer, missing only a single game. He coached from a golf cart when the burning sensation in his feet made it too painful to stand. And when he was sidelined that one Friday night after a blood clot required surgery, he phoned his players from his hospital bed to wish them luck.

With a state title at Eunice High School, after runner-up finishes there in 1997 and 1998, Trosclair had reached the pinnacle of a long, successful career. He was one of Louisianas winningest coaches. Back home on the Cajun prairie, he rode in a convertible during the towns victory parade, holding the championship trophy. He had nothing left to prove, but he stayed on for the 2019 season, elevating his career record to 247 victories even as medication left him with muscle cramps so severe at times that his fork fell from his fingers.

I couldnt pull the trigger, Trosclair, 64, said in a telephone interview. Its hard to walk away.

Now, he feels compelled, becoming one of a number of older coaches across the country who are choosing to retire rather than risk their health in the coronavirus pandemic.

In June, he gave his retirement notice after 40 years of coaching, the last 25 years at Eunice High. His cancer was in remission but his immune system was compromised. He did not think he could remain safe when a new school year and a new football season began. Not in a locker room where his players dress shoulder to shoulder. Not in the weight room. Not in crowded school hallways.

My doctors thought it was in my best interest not to coach, Trosclair said. I was on the edge; the coronavirus got me to jump over.

While young athletes are considered less vulnerable to Covid-19, the disease caused by the coronavirus, aging coaches are at higher risk of infection and having a severe response. At least 30 high school and club team coaches have died of coronavirus-related causes, according to a search of online obituaries. Though some were in their 70s, one was 27, another 30.

Countless other coaches have been forced to reconsider whether it is worth risking their health to continue their careers.

It remains unclear how many coaches have retired for reasons related to Covid-19. The N.C.A.A., the National Federation of State High School Associations, state athletic associations and coaching organizations said they have not kept such figures.

But a number of states have reported an uptick in teacher retirements, even if it is uncertain how many are related to the coronavirus. Louisiana, for instance, reported 335 retirements in August compared with 196 that month in 2019. In Ohio, the retirement rate more than doubled from July 1 through mid-August, compared to that period a year ago.

More so than in previous years, we are hearing about coaching staff retirees, said Jennifer Mann, a data technician with the Clell Wade Coaches Directory, a well-regarded national networking tool for coaches that tracks collegiate, high school and junior high school sports.

Even so, they may represent a fraction of coaches, though their departures often are deeply felt in their communities.

There are hundreds of thousands of high school coaches across the country in various sports, so even if there are hundreds who have retired, it is a pretty small number, Bruce Howard, a spokesman for the national high school federation, said in an email.

Some coaches who walked away said the pandemic had led them into deep introspection about their safety and their lifes direction.

Norm Ogilvie, 60, Duke Universitys longtime track and field coach, said in a statement that he felt there needs to be a final meaningful chapter for the remaining years I have on our rapidly changing planet.

Mike Fox, 64, retired after 22 years and seven trips to the College World Series as the baseball coach at the University of North Carolina. The coronavirus, he told the school, made him realize it is time for me to be a full-time husband, father and grandfather and do other things with my life.

Updated Sept. 18, 2020

Heres whats happening as the world of sports slowly comes back to life:

Joe Bustos, 57, who won two Arizona state basketball championships in 23 seasons coaching at North High School in Phoenix, stepped down, expressing frustration with virtual teaching and concern after two Arizona teachers died over the summer of Covid-19, including a 61-year-old high school swimming coach.

Im just afraid; I dont want to be playing Russian roulette, Bustos said in an interview. I love coaching and teaching, but at the end of the day youve got to look out for yourself.

Peter Kingsley, 54, taught middle school for nearly three decades in Boulder, Colo., and coached football, basketball, wrestling and track. But he has epilepsy and a circulatory condition that leaves him predisposed to strokes. His wife urged him to retire because of the pandemic. And he was influenced by spending 22 days in hospice with his father, who died this summer of bone cancer.

I had a choice to make whether to potentially die or keep coaching and teaching, Kingsley said in a telephone interview. I just needed to stay safe.

Trosclairs decision to leave coaching in Louisiana came reluctantly, after battling a cancer that he had never heard of until he learned he had it.

In spring 2014, he began to experience dizzy spells and fatigue. His blood pressure rose and his kidneys began to fail. The diagnosis was multiple myeloma, which begins in the bone marrow and limits the bodys ability to fight off infections, weakens bones, reduces kidney function and lowers a persons red blood cell count.

Trosclair began chemotherapy and taking a corticosteroid called Decadron, which left him intensely focused, insatiably hungry and agitated from extreme insomnia followed by bouts of crashing. He recalls his oncologist at the M.D. Anderson Cancer Center in Houston saying that he might lose his job in such a severe state. He jokingly replied, They already think Im crazy, so theyll give me a pass.

He asked one of his assistant coaches to remain vigilant in case his temper flared. Some days he felt 20 years old, he told a Louisiana reporter. Other days he felt 100. Still, Trosclair coached every game in the 2014 football season. In early 2015, he underwent a stem cell transplant. His own blood-making stem cells were harvested, frozen, then reintroduced after chemotherapy to produce new, healthy blood cells. He spent six weeks in Houston for the treatment and recovery.

People in Eunice raised some money and it was a big help, Trosclair said.

Months later, though, a mix-up over blood thinners during the 2015 football season led to a blood clot in his left leg and forced him into intensive care at a hospital in Lafayette, La. His left foot swelled to three times its normal size. Three surgeries were required, causing him to miss his only game in 25 seasons. Trosclair spoke to his team beforehand by phone, saying, I love you. Go out and play.

Irma Trosclair, his wife and the superintendent of schools in Lafayette Parish, one of Louisianas largest school districts, still keeps a video of the bedside pep talk.

When I saw him doing that, with all those tubes he had going, I knew that coaching wasnt just work, she said. It was what was going to pull him through.

In 2018, Eunice High unexpectedly reached the Class 3A state championship game and prevailed, 59-47, with Trosclairs Wing-T offense, an intricate symphony of misdirection and strategic passing. After a quarter century at the school and five seasons of fighting cancer, he claimed his biggest football victory. Trosclair told a television interviewer, It was like the universe opened its doors and said, here you go, heres a gift for you.

The high school and its football team confirm that Eunice still measures up, even as its population and student enrollment continue to shrink and a third of its 9,800 residents live in poverty. It is the only traditional public high school in St. Landry Parish to carry an A-rating of academic performance from the state and has maintained its diversity a half century after desegregation.

When you think of Eunice High, you think of Coach Trosclair, said the principal, Mitch Fontenot. Everybody looks up to him. He has a real calming effect. Its a big loss.

Sixteen starters were to return for the 2020 season. Another deep playoff run seemed possible. But the coronavirus shuttered Louisiana schools in March and the state became a hot spot. Trosclair no longer felt he could protect himself and manage his team safely at the same time. Retirement began to seem inevitable.

On June 18, Trosclair saw Dr. Donna M. Weber, his oncologist at M.D. Anderson, who wrote in a letter that he was at particular risk of infection during the pandemic and that she advised him not to return to work.

Irma Trosclair said, He needed his doctor to tell him he absolutely had no other option. I think hes very much at peace with it.

There has been sobering validation of Trosclairs decision. The athletic director of an area high school also retired with multiple myeloma. The father of one of Trosclairs former players died of Covid-19. Trosclairs replacement at Eunice High, interim coach Andre Vige, 41, tested positive, along with two Eunice High players, one of whom was hospitalized. All have recovered. Two teenage brothers in the area, the youngest a football player, also contracted the virus. The elder brother died at age 19.

Its possible for young people to die, Trosclair said. Thats the scary thing.

He spent the summer playing golf, taking 6 a.m. walks around the Eunice High track and lifting weights at the school when no one was around. He takes Revlimid, a maintenance medication, three weeks of every four. And while fatigue and muscle spasms persist, acupuncture has helped relieve the burning feeling in his feet. His red blood cell count and other markers are encouraging. Still, he has avoided large gatherings.

When the Eunice city council honored him, his wife went in his place. His grandchildren have not visited since March. When his youngest son, Trenon, 26, got married in June, Trosclair sat in an isolated section of the church, then left through a side door and skipped the reception.

Im really sad right now, he texted his wife.

Louisianas delayed high school football season is set to begin on Oct. 1. Trosclair would like to remain involved with the team in some manner. He has studied plays at the dining room table with Trenon, the teams secondary coach. Perhaps he will help with game planning. He would like to attend games, if he can stand away from everyone, but his wife is skeptical. She has another idea.

Hopefully theyll let me keep my same parking spot, Irma Trosclair said. Then we can watch the whole game from my vehicle. Surely theyll grant that for Coach.

Gillian Brassil contributed reporting. Sheelagh McNeill and Susan Beachy contributed research.

Continue reading here:
The Pandemic Is Chasing Aging Coaches From the Field - The New York Times

Recommendation and review posted by Bethany Smith

How Is Cryonics Performed? – How Cryonics Works …

If you decide to have yourself placed in cryonic suspension, what happens to you? Well, first, you have to join a cryonics facility and pay an annual membership fee (in the area of $400 a year). Then, when your heart stops beating and you are pronounced "legally dead," an emergency response team from the facility springs into action. The team stabilizes your body, supplying your brain with enough oxygen and blood to preserve minimal function until you can be transported to the suspension facility. Your body is packed in ice and injected with heparin (an anticoagulant) to prevent your blood from clotting during the trip. A medical team awaits the arrival of your body at the cryonics facility.

Once you are transported to the cryonics facility, the actual "freezing" begins. Cryonics facilities can't simply put their patients into a vat of liquid nitrogen, because the water inside their cells would freeze. When water freezes, it expands -- this would cause the cells to simply shatter. The cryonics team must first remove the water from your cells and replace it with a glycerol-based chemical mixture called a cryoprotectant -- a sort of human antifreeze. The goal is to protect the organs and tissues from forming ice crystals at extremely low temperatures. This process, called vitrification (deep cooling without freezing), puts the cells into a state of suspended animation.


Once the water in your body is replaced with the cryoprotectant, your body is cooled on a bed of dry ice until it reaches -130 C (-202 F), completing the vitrification process. The next step is to insert your body into an individual container that is then placed into a large metal tank filled with liquid nitrogen at a temperature of around -196 degrees Celsius (-320 degrees Fahrenheit). Your body is stored head down, so if there were ever a leak in the tank, your brain would stay immersed in the freezing liquid.

Cryonics isn't cheap -- it can cost up to $150,000 to have your whole body preserved. But for the more frugal futurists, a mere $50,000 will preserve your brain for perpetuity -- an option known as neurosuspension. Hopefully for those who have been preserved this way, technology will come up with a way to clone or regenerate the rest of the body.

If you opt for cryonic suspension, expect to have some company. Several bodies and/or heads are often stored together in the same liquid-nitrogen-filled tank.

See the original post here:
How Is Cryonics Performed? - How Cryonics Works ...

Recommendation and review posted by Bethany Smith

Netflix’s Hope Frozen: A Quest To Live Twice Review: A Hope To Be Resurrected | TechQuila – TechQuila

- Advertisement -

Hope Frozen: A Quest To Live Twice premiered on 15th September 2020. Directed by Pailin Wedel, the documentary takes us closer to the Naovaratpong family whose daughter is the youngest cryogenically frozen person, after her sudden demise due to brain cancer.

Hope Frozen: A Quest To Live Twice revolves around the lives of the Naovaratpong family who decided to cryogenically freeze their daughter Einz (meaning love) who, at the age of 2 years, unexpectedly fell into a coma due to a fatal form of brain cancer that has 0% survival rate. After multiple surgeries and procedures, Einz lost her battle. But before her demise, the family contacteda company in Arizona called Alticor, who agreed to cryogenically preserve her remains for the future.

Cryogenically freezing refers to a procedure where an individuals corpse or severed head is preserved at a low temperature (196 C or 320.8 F) with the speculative hope that resurrection may be possible in the future with technological advancements and treatment availability. The Naovaratpong family took this decision in order to preserve their daughter today but to revive her someday in the future in a better world where there is a cure for her fatal cancer.

- Advertisement -

The family faced a lot of backlash from the media as everyone believed that the family stopped the childs soul from reincarnating or trapped the soulless body of their child, and questioned their decision both in the name of science and religion.

The documentary in itself carries a lot of questions related to science, ethics, and religious philosophy. While I felt the plight of the parents and, to an extent, understood what they did and why they did so, on the other hand, their decision stopped them from moving ahead. A piece of them, which is physically dead, still remained in the hope of revival someday. The presence of undying hope and optimism is great but too much of anything can be painful.

While reading more about the whole scenario, I found out that Einzs body wasnt preserved, but rather, what remained of her cancer-affected brain. While Einz and brother Matrix shared a heartwarming bond, after her demise, he decided to progressively look forward with hope and inquisitiveness, and contribute towards science. While his decision is very strong and heartwarming, I felt there was a constant, unconscious pressure on him to do something for his sister, something thatll take years of work with little to no success rate.

- Advertisement -

Matrix visits the chamber where his sister is kept and places a card on it that read You are your own unique story. The sentiment is both strong and odd and speaks volumes.

STREAM IT! Hope Frozen: A Quest To Live Twice is a story of hope, optimism, love, science, parenthood, and grief. The documentary isnt exactly loaded with facts and figures but takes you closer to a family who are widely misunderstood and criticized. Definitely, a worthy watch!

- Advertisement -

The cultural code followed in the documentary takes us closer to the family and does not fancy the mise-en-scene. The simple making and close-knit storyline makes this documentary both heartwarming and heart wrenching. The narrative elements and balance allow it to interact with the viewers, giving them an insight into the reality and the world cryonics!

Hope Frozen: A Quest to Live Twice is now streaming on Netflix.

Read our other reviewshere.

- Advertisement -

See original here:
Netflix's Hope Frozen: A Quest To Live Twice Review: A Hope To Be Resurrected | TechQuila - TechQuila

Recommendation and review posted by Bethany Smith

Public will soon be able to spot cheetahs in Rietvlei – IOL

By Zelda Venter 16h ago

Share this article:

Fans of the Rietvlei Nature Reserve are looking forward to the day they can be on the lookout for its two new cheetahs.

Njozi, a sub-adult female cheetah which arrived last month, now has a mate, a male sub-adult released in the popular Pretoria city reserve last week.

For now they cannot be seen by the visiting public as they are being kept in a cordoned-off boma to give them a chance to settle.

They will stay together in the reserve until it is time for the male to be relocated the hope is they will produce a litter, as was the case with previous cheetahs in the reserve.

The two took to each other like ducks to water, said Vincent van der Merwe of the Endangered Wildlife Trust (EWT), and they are settling and should be released into the wider reserve by the end of September.

Van der Merwe said it had been an anxious time when the male from Welgevonden was released as they did not know how Njozi would react. She had come from a family in the Western Cape and been skittish at first, but became more confident with time.

He said they were ready to separate the two if they got in a fight, but it was not necessary. Instead, Njozi called out to the male and when he approached, they licked one another.

They are very relaxed with each other and bonded nicely. Lets see how they adapt to their new surroundings when we release them, he said.

He described the new male as a beautiful animal with a mix of Karoo and Namibian genetics.

Knowledge of cheetahs has grown fast and the EWT has had success with its metapopulation project for the long-term viability of cheetahs in smaller fenced reserves, and with the long-term genetic and demographic integrity of the metapopulation across Africa.

Funds to support the project have come from CRC Industries, Q20 SA, Lions Club of Pretoria City and Strata Logistics.

In 2017, Kiara and Sabona produced a litter of three cubs, the first time cheetah cubs had been born in the reserve, and they were a hit with visitors until their relocation.

Public will soon be able to spot cheetahs in Rietvlei - IOL

Recommendation and review posted by Bethany Smith

Male Breast Cancer Treatment Market Size will Observe Substantial Growth by 2026 | Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis – The Daily…

This report additionally covers the effect of COVID-19 on the worldwide market. The pandemic brought about by Coronavirus (COVID-19) has influenced each part of life all inclusive, including the business segment. This has brought along a several changes in economic situations.

This report focuses on the Global Male Breast Cancer Treatment Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

Download Premium Sample of the Report:

PfizerRocheGlaxoSmithKlineSanofiNovartisBayerBristol-Myers SquibbEli LillyAstraZenecaTeva PharmaceuticalSun PharmaceuticalBioNumerik PharmaceuticalsSeattle GeneticsAccord Healthcare

By Type:


By Application:


Regional Analysis of the Male Breast Cancer Treatment Market:

Additionally, the report serves as a convenient guide to design and implement potential growth steering activities across select regional pockets in the Male Breast Cancer Treatment market. Frontline players and their effective growth strategies are also enlisted in the report to emulate growth.

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

Middle East and Africa (Turkey, GCC, Rest of Middle East)

Customization of this Report: This Male Breast Cancer Treatment market report could be customized to the customers requirements. Please contact our sales professional ([emailprotected]), we will ensure you obtain the report which works for your needs.

Key Questions Answered in this Report:

What is the outlook for the Male Breast Cancer Treatmentindustry?This report has over a dozen market forecasts (2020 and the next 5 years) on the industry, including total sales, a number of companies, attractive investment opportunities, operating expenses, and others.

What industry analysis/data exists for the Male Breast Cancer Treatmentindustry?This report covers key segments and sub-segments, key drivers, restraints, opportunities, and challenges in the market and how they are expected to impact the Male Breast Cancer Treatmentindustry. Take a look at the table of contents below to see the scope of analysis and data on the industry.

How many companies are in the Male Breast Cancer Treatmentindustry?This report analyzes the historical and forecasted number of companies, locations in the industry, and breaks them down by company size over time. The report also provides company rank against its competitors with respect to revenue, profit comparison, operational efficiency, cost competitiveness, and market capitalization.

What is the market size of the Male Breast Cancer Treatmentindustry?This report covers the historical market size of the industry (2013-2020), and forecasts for 2020 and the next 5 years. Market size includes the total revenues of companies.

What are the financial metrics for the industry?This report covers many financial metrics for the industry including profitability, Market value- chain, and key trends impacting every node with reference to the companys growth, revenue, return on sales, etc.

What are the most important benchmarks for the Male Breast Cancer Treatmentindustry?Some of the most important benchmarks for the industry include sales growth, productivity (revenue), operating expense breakdown, span of control, organizational make-up. All of which youll find in this market report.

Request Customization of the Report:

If you want to need latest primary and secondary data (2020-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key Points from Table of Content:

1 Market Overview1.1 Product Definition and Market Characteristics1.2 Global Male Breast Cancer Treatment Market Size1.3 Market Segmentation1.4 Global Macroeconomic Analysis1.5 SWOT Analysis

2. Market Dynamics2.1 Market Drivers2.2 Market Constraints and Challenges2.3 Emerging Market Trends2.4 Impact of COVID-192.4.1 Short-term Impact2.4.2 Long-term Impact

3 Associated Industry Assessment3.1 Supply Chain Analysis3.2 Industry Active Participants3.2.1 Suppliers of Raw Materials3.2.2 Key Distributors/Retailers3.3 Alternative Analysis3.4 The Impact of Covid-19 From the Perspective of Industry Chain

4 Market Competitive Landscape4.1 Industry Leading Players4.2 Industry News4.2.1 Key Product Launch News4.2.2 MandA and Expansion Plans

5 Analysis of Leading Companies5.1 Company 15.1.1 Company 1 Company Profile5.1.2 Company 1 Business Overview5.1.3 Company 1 Male Breast Cancer Treatment Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.1.4 Company 1 Male Breast Cancer Treatment Products Introduction

5.2 Company 25.2.1 Company 2 Company Profile5.2.2 Company 2 Business Overview5.2.3 Company 2 Male Breast Cancer Treatment Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.2.4 Company 2 Male Breast Cancer Treatment Products Introduction

5.3 Company 35.3.1 Company 3 Company Profile5.3.2 Company 3 Business Overview5.3.3 Company 3 Male Breast Cancer Treatment Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.3.4 Company 3 Male Breast Cancer Treatment Products Introduction

5.4 Company 45.4.1 Company 4 Company Profile5.4.2 Company 4 Business Overview5.4.3 Company 4 Male Breast Cancer Treatment Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.4.4 Company 4 Male Breast Cancer Treatment Products Introduction

6 Market Analysis and Forecast, By Product Types6.1 Global Male Breast Cancer Treatment Sales, Revenue and Market Share by Types (2015-2020)6.2 Global Male Breast Cancer Treatment Market Forecast by Types (2020-2026)6.3 Global Male Breast Cancer Treatment Sales, Price and Growth Rate by Types (2015-2020)6.4 Global Male Breast Cancer Treatment Market Revenue and Sales Forecast, by Types (2020-2026)

7 Market Analysis and Forecast, By Applications7.1 Global Male Breast Cancer Treatment Sales, Revenue and Market Share by Applications (2015-2020)7.2 Global Male Breast Cancer Treatment Market Forecast by Applications (2020-2026)7.3 Global Revenue, Sales and Growth Rate by Applications (2015-2020)7.4 Global Male Breast Cancer Treatment Market Revenue and Sales Forecast, by Applications (2020-2026)

Request TOC:

8 Market Analysis and Forecast, By Regions8.1 Global Male Breast Cancer Treatment Sales by Regions (2015-2020)8.2 Global Male Breast Cancer Treatment Market Revenue by Regions (2015-2020)8.3 Global Male Breast Cancer Treatment Market Forecast by Regions (2020-2026)Continued.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540




Follows to Twitter :

Follows to LinkedIn :

Here is the original post:
Male Breast Cancer Treatment Market Size will Observe Substantial Growth by 2026 | Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis - The Daily...

Recommendation and review posted by Bethany Smith

Seattle Genetics and Astellas Announce PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated…

Sept. 18, 2020 10:45 UTC

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) today announced that a phase 3 trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy. The results were reviewed by an independent Data Monitoring Committee following a planned interim analysis. The global EV-301 clinical trial compared PADCEV to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor.

This press release features multimedia. View the full release here:

PADCEV (enfortumab vedotin-ejfv) (Photo: Business Wire)

In the trial, PADCEV significantly improved overall survival (OS), with a 30 percent reduction in risk of death (Hazard Ratio [HR]=0.70; [95% Confidence Interval (CI): 0.56, 0.89]; p=0.001). PADCEV also significantly improved progression-free survival (PFS), a secondary endpoint, with a 39 percent reduction in risk of disease progression or death (HR=0.61 [95% CI: 0.50, 0.75]; p<0.00001).

For patients in the PADCEV arm of the trial, adverse events were consistent with those listed in the U.S. Prescribing Information, with rash, hyperglycemia, decreased neutrophil count, fatigue, anemia and decreased appetite as the most frequent Grade 3 or greater adverse event(s) occurring in more than 5 percent of patients. Data from EV-301 will be submitted for presentation at an upcoming scientific congress. Patients in the chemotherapy arm of the trial will be offered the opportunity to receive PADCEV.

The results will be submitted to the U.S. Food and Drug Administration (FDA) as the confirmatory trial following the drugs accelerated approval in 2019. EV-301 is also intended to support global registrations.

These survival results from the confirmatory trial for PADCEV are welcome news for patients whose cancer has progressed after platinum-based chemotherapy and immunotherapy, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. We continue to explore PADCEVs activity across the spectrum of urothelial cancer including its potential for use in earlier lines of therapy.

EV-301 is the first randomized trial to show overall survival results compared to chemotherapy in patients with locally advanced or metastatic urothelial cancer who previously have received platinum-based treatment and a PD-1 or PD-L1 inhibitor, and we are encouraged by the potential this may have in helping patients who have otherwise limited alternatives, said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head, Astellas. We look forward to discussing these results with global health authorities.

Globally, approximately 580,000 people will be diagnosed with bladder cancer in 2020.1 Urothelial cancer accounts for 90 percent of all bladder cancers and can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra.2 Approximately 80 percent of people do not respond to PD-1 or PD-L1 inhibitors after a platinum-containing therapy has failed as an initial treatment for advanced disease.3

About the EV-301 Trial

The EV-301 trial (NCT03474107) is a global, multicenter, open-label, randomized phase 3 trial designed to evaluate PADCEV versus physician's choice of chemotherapy (docetaxel, paclitaxel or vinflunine) in approximately 600 patients with locally advanced or metastatic urothelial cancer who were previously treated with a PD-1 or PD-L1 inhibitor and platinum-based therapies. The primary endpoint is overall survival of participants treated with PADCEV compared to those treated with chemotherapy. Secondary endpoints include progression-free survival, duration of response, and overall response rate, as well as assessment of safety/tolerability and quality-of-life parameters.

For more information about the EV-301 clinical trial, please visit

About PADCEV (enfortumab vedotin-ejfv)

PADCEV was approved by the U.S. Food and Drug Administration (FDA) in December 2019 and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting. PADCEV was approved under the FDAs Accelerated Approval Program based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.4

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.4,5 Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).4 PADCEV is co-developed by Astellas and Seattle Genetics.

PADCEV Important Safety Information

Warnings and Precautions

Adverse Reactions

Serious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions (20%) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade 3 adverse reactions (5%) were rash (13%), diarrhea (6%) and fatigue (6%).

Lab Abnormalities

In one clinical trial, Grade 3-4 laboratory abnormalities reported in 5% were: lymphocytes decreased (10%), hemoglobin decreased (10%), phosphate decreased (10%), lipase increased (9%), sodium decreased (8%), glucose increased (8%), urate increased (7%), neutrophils decreased (5%).

Drug Interactions

Specific Populations

For more information, please see the full Prescribing Information for PADCEV here.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in peoples lives. The company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit and follow @SeattleGenetics on Twitter.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at

About the Seattle Genetics and Astellas Collaboration

Seattle Genetics and Astellas are co-developing PADCEV (enfortumab vedotin-ejfv) under a 50:50 worldwide development and commercialization collaboration that was entered into in 2007 and expanded in 2009.

Seattle Genetics Forward Looking Statements

Certain statements made in this press release are forward looking, such as those, among others, relating to the submission of data from the EV-301 trial for presentation at an upcoming scientific congress; intended regulatory actions, including plans to submit the results of the EV-301 trial to the FDA as the confirmatory trial following the drugs accelerated approval in the U.S. and plans to discuss the results with global health authorities and seek global registrations; conduct of a comprehensive clinical development program for PADCEV, which includes exploring PADCEVs activity in other types of urothelial cancer and its potential for use in earlier lines of therapy; the therapeutic potential of PADCEV, including its efficacy, safety and therapeutic uses, and anticipated development activities, including ongoing and future clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include that the data from the EV-301 trial may not be selected for presentation at scientific congresses; the possibility of delays in the submission of results to the FDA; that the results from the EV-301 trial may not be enough to convert PADCEVs accelerated approval in the U.S. to regular approval or to support any other global registrations; that, even if PADCEV receives regular approval in the U.S. or any other global registrations, the product labeling may not be as broad or desirable as anticipated; the possibility that ongoing and subsequent clinical trials may fail to establish sufficient activity; the risk of adverse events or safety signals; and the possibility that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Astellas Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on managements current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

1 International Agency for Research on Cancer. Cancer Tomorrow: Bladder. Accessed 07-31-2020.2 American Society of Clinical Oncology. Bladder cancer: introduction (10-2017).3 Shah, Manasee V., et al Targeted Literature Review of the Burden of Illness in UC (PCN108), Nov 2018.4 PADCEV [package insert] Northbrook, IL: Astellas, Inc.5 Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.

View source version on

Go here to see the original:
Seattle Genetics and Astellas Announce PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated...

Recommendation and review posted by Bethany Smith

Global Male Breast Cancer Treatment Market to Rise at a CAGR of XX% Due to COVID-19 Outbreak Exclusive Report Covering: Pfizer, Roche,…

(Sep, 2020) United Kingdom, The report titled Male Breast Cancer Treatment Market: Size, Trends and Forecasts (2020-2026), delivers an in-depth analysis of the Male Breast Cancer Treatment Industry by considering there type, application, market value, by production capacity, by companies, by region, etc.

The report assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the Male Breast Cancer Treatmentindustry. Growth of the overall Male Breast Cancer Treatmentmarket has also been forecasted for the period 2020-2026, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Get Exclusive Sample copy on Male Breast Cancer Treatment Marketis available at

Male Breast Cancer TreatmentMarket report analyses the impact of Coronavirus (COVID-19) on theMale Breast Cancer Treatmentindustry.

Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

If you are investor/shareholder in theMale Breast Cancer TreatmentMarket, the provided study will help you to understand the growth model ofMale Breast Cancer TreatmentIndustry after impact of COVID-19. Request for sample report (including ToC, Tables and Figures with detailed information) @

The research report segments the market from a relevancy perspective into the below segments and sub-segments with the quantitative analysis done from 2017 to 2026 considering 2019 as the base year for the research. Compounded Annual Growth Rate (CAGR) for each respective segment and sub-segment is calculated for the forecast period from 2019 to 2026 to provide a reference for growth potential.

Male Breast Cancer Treatmentmarket segmented on the basis of Product Type:Medication, Chemotherapy, Others

Male Breast Cancer Treatmentmarket segmented on the basis of Application: Hospitals, Clinics, Others

The major players profiled in this report include:Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, Accord Healthcare

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List;

Regional Coverage of theMale Breast Cancer TreatmentMarket:

Reasons to PurchaseMale Breast Cancer TreatmentMarket Research Report


Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

See more here:
Global Male Breast Cancer Treatment Market to Rise at a CAGR of XX% Due to COVID-19 Outbreak Exclusive Report Covering: Pfizer, Roche,...

Recommendation and review posted by Bethany Smith

The Undark Interview: A Conversation with Rita Colwell – Undark Magazine

Rita Colwell is a pioneering microbiologist whose work on cholera helped illuminate the interplay between the environment and public health. She was also the first woman to serve as director of the National Science Foundation, and is currently a Distinguished University Professor at both the University of Maryland and Johns Hopkins Universitys Bloomberg School of Public Health.

In her half-century-plus in the sciences, Colwell has also seen very clearly the array of obstacles confronted by women as they try to navigate a traditionally male world. (When she applied for a graduate fellowship in bacteriology, she says was told, We dont waste fellowships on women.)

A Lab of Ones Own: One Womans Personal Journey Through Sexism in Science, by Rita Colwell and Sharon Bertsch McGrayne (Simon & Schuster, 288 pages).

Colwells new book, A Lab of Ones Own, co-authored with writer Sharon Bertsch McGrayne, documents much of what she has seen and heard over the years, from sexual harassment to the invisible structural obstacles placed in the way of women working in the sciences. (The books subtitle is One Womans Personal Journey Through Sexism in Science.)

Not long ago, women were discouraged from studying science at all; those who did pursue such studies were seen as oddities. Later, when the numbers of women earning science degrees began to rise, they found themselves receiving less funding than their male colleagues, and less likely to land a position as a professor or a lab director. (It wasnt that long ago, Colwell recalls, when a grant application could be turned down because a man on the granting committee simply didnt like women scientists.) But Colwell also found allies along the way, and her book is something of a celebration of what can be achieved when science strives for inclusivity.

The following interview has been edited for length and clarity.

UNDARK: Though sexism has a long history, you write that the 1950s and 60s saw unprecedented levels of sexism in the sciences. What was going on at that time?

Rita Colwell: The attitude was, a woman worked in the home period. A woman couldnt even get a credit card in her own name; she had to have her husband, or her father, vouch for her. In general, the understanding was, if you were [a woman] interested in science, that was peculiar. It wasnt unusual for women to go to college but most did not go from there into any kind of work, unless it was nursing or teaching. It was a very limiting time, for women. A lot of this was unspoken; it was just sort of assumed.

UD: Regarding graduate education, you say that women were simply seen as not worth investing in. What does that mean?

RC: The expectation was that you would get married and have children. If you werent there, with your children, you were seen as a bad mother. You went to college to find a husband; that was the expectation.

UD: You point out that not only could one face obstacles for being a woman Ph.D. student, you could face a backlash if you supervised too many women Ph.D. students. What was that about?

RC: The assumption was that anyone who was really brilliant, with great ideas, would work for a male professor. So if you took women students, it was assumed they werent the best and the brightest. Having women students would mark you as not serious; your students were just going to get married, and youre just wasting all this time.

UD: As you say, a lot of this was unspoken but eventually there was solid data to quantify this discrimination. How did that come about?

RC: It was in the 90s that Nancy Hopkins at MIT carried out her now-famous experiment: She measured the labs, and discovered that the men had almost twice as much space; they also got the bulk of the research money. More women were entering these careers [in the sciences], but men got most of the funding and most of the space.

Later, Jo Handelsman did the experiment where they sent identical letters to male researchers [from recent graduates applying to be a lab manager], the only difference was that some were signed John and others were signed Jennifer. The question was, would you hire this person, and what would you pay them? Far fewer said they would hire the woman; and the salary they were prepared to offer was much, much lower.

But Id like to emphasize one thing: Once I was able to break through, at each stage of my career, there was tremendous support. My father was very education-minded; it didnt matter if you were a girl or a boy; everyone went to school. My husband, a physicist, was a fantastic supporter; we were married for 62 very happy years. And my Ph.D. supervisor, John Liston, was absolutely the best. He was a newcomer to the University of Washington, starting a new program in marine microbiology so I ended up being the first graduate student with a Ph.D. in marine microbiology, possibly in the whole United States.

The assumption was that anyone who was really brilliant, with great ideas, would work for a male professor. So if you took women students, it was assumed they werent the best and the brightest.

UD: Youre known for your groundbreaking work on cholera, but it was also fascinating to read about your work investigating the 2001 anthrax attacks, in which a number of politicians and journalists were mailed packages containing the deadly substance in the weeks following the 9/11 attacks. How did you end up on the front lines of that investigation?

RC: I was appointed [as director of the National Science Foundation] by Bill Clinton, and I served two years under Clinton and four under George W. Bush. In October or November [of 2001], we heard about anthrax attacks. I remember saying, Weve got to sequence that bacterium, or well never know who did it.

I had been working on an advisory board for the CIA, so I was able to call on some colleagues, and we formed an inter-agency group. We decided not to make the group official, so that we could keep it a secret. And we worked for five years on this classified project. And using molecular genetics, we tracked down the source. Now, well never know whether the perpetrator was in fact Bruce Ivins, and if he worked alone, or with others. [Ivins died in 2008.] He was an anthrax microbiologist, and the source turned out to be in his lab.

UD: You were using a computer in the late 1950s, long before they became ubiquitous in the life sciences. Did you have a sense that computers would eventually impact every branch of science?

RC: At the University of Washington, I wrote a computer program the first in the country, for bacteriology using the old IBM 650, which has less power than the chip in your microwave oven. When I was working with that computer, I had to program it, and I didnt know diddly. But in my husbands lab, there was a postdoc named George Constabaris, who taught me. And there was another chap who was using the IBM to do pipe-fitting for the ships in Seattle harbor. He was programming how to cut and fit pipe most efficiently.

So it was clear to me that this was an amazing tool. I used the computer for taxonomic purposes, for identification which now everybody does. Its amusing I used to give talks about species of bacteria, and people would yawn. But now the hotshots in Silicon Valley know the differences between different kinds of bacteria. It was clear to me that we had to have massive computation [in the sciences]. I was able to get into the NSF budget, over my term, $2 billion, for computation, for universities to start building the internet railway, so to speak.

UD: So much has changed in science, and in the culture of science, over your career. Today, are you optimistic or at least, more optimistic?

RC: I would say its cautious optimism. I dont know whats going to happen in the next administration; it could be a disaster for women. I strongly encourage girls to go into science. I abhor the assumption that girls cant do math; its absurd. Or that if youre African American you cant do math or you cant do science its crazy. Theres still sexism, which ranges from the criminal to the clueless. Like when someone comments to a woman scientist as shes going up to the podium to give a talk, that she looks attractive. Thats the last thing you want to hear. You want to hear Thats a great idea, or Can we collaborate on the next stage of this experiment?

The Undark Interview: A Conversation with Rita Colwell - Undark Magazine

Recommendation and review posted by Bethany Smith

Is Malaysia the cradle of civilisation? | Free Malaysia Today – Free Malaysia Today

When I was younger, the Hollywood blockbuster The Mummy enraptured and captured my attention like few other movies did. Its mesmerising mixture of Egyptian myth and cinematic mayhem sparked a lifelong fascination in me for mysterious, ancient civilisations.

However, one thing I noticed over the years was how Malaysia and Southeast Asia were largely absent from the discussion when it came to ancient civilisations. There were tales about the Sumerians, Babylonians, Egyptians, Indians, and Chinese but never Malaysians or rather those who inhabited Malaysia at the time.

For a long time, we were thought to be at the periphery of prehistory, so we were often relegated to a footnote, and sometimes not even that. Our history textbooks certainly didnt help they concentrated the bulk of their focus on the Malacca sultanate and the events that followed after (post-1400 AD), dedicating just a few cursory sections to powerful regional kingdoms that predated it such as Langkasuka, Majapahit, Srivijaya, and Kedah Tua. Their details on prehistory are even abysmally scantier.

When I dug deeper, I realised why. In addition to there being little archaeological, geological, and literary evidence to go by, the prevailing scientific consensus was that those who came to inhabit the Malay peninsula and Borneo were descendants of ancient argonauts from Taiwan who colonised Malaysia and other parts of Southeast Asia only as recently as 4,000 years ago.

Called the Out-of-Taiwan Theory, it was largely based on exiguous archaeological findings and linguistic population mapping. Since we were considered a relatively young offshoot culture who inherited agriculture and other neolithic technology from the seafaring ancient aboriginal Taiwanese (the Formosans), we were not of much interest to many prehistorians and archaeologists.

But a potentially paradigm-shifting theory posited by Oxford geneticist Stephen Oppenheimer threatens to upend this long-standing view. While his predecessors used archaeology, geology, and linguistics to investigate the subject, Oppenheimer and his colleagues have added a new, powerful tool to the mix genetics.

The key to the theory is the study of the often marginalised and sometimes even criminally disenfranchised Orang Asli.

Oppenheimer and his colleagues pored through the Orang Aslis female mtDNA (mitochondrial DNA) and the male Y chromosome the two components of the human genetic code that dont get shuffled like nuclear DNA does during reproduction, hence maintaining their purity and making them powerful portals into our past.

Thanks to this study and the discovery of many other geological, linguistic, and archaeological markers, a new theory that reverses and predates the Out-of-Taiwan Theory has emerged. Its called the Out-of-Sundaland Theory.

This groundbreaking theory puts Malaysia and Southeast Asia at the heart of prehistoric innovation and civilisation and makes the Orang Asli the probable progenitors of the ancient cultures that would go on to dominate the world.

According to the theory, there was a single migration of anatomically modern humans out of Africa around 80,000 years ago. These pioneering beachcombers traversed the Arabian and Indian coasts, eventually making it to the lands now known as Malaysia and Southeast Asia around 60,000 years ago.

Oppenheimer says: The ancestors of the three Orang Asli groups (the Senai, Semang, and Proto-Malays) in the Malay peninsula arrived in the vanguard. They (the Orang Asli) descended from the very first people who put foot in this region in Malaya.

But when the ancestors of the Orang Asli set foot here, Malaysia didnt look like it does now far from it. At the time, it wasnt a snaking peninsula with a large island on the east.

Instead, it was part of a gargantuan, trunk-like subcontinent double the size of India the result of sea levels being at least 120 metres lower than they are currently. This means that modern-day Malaysia, Thailand, Indonesia, Singapore, and all the now-submerged land between them were connected and formed one solid, massive peninsula.

This majestic, prehistoric landmass is aptly called Sundaland Sund being the Sanskrit term for an elephants trunk.

Thanks to its fortuitously strategic geography, where it hugs the equator and is flanked by the sea, it was Eden-like full of dense, life-sustaining vegetation, frequent rainfall, and populated by animals of all kinds. Many of our ancestors, presumably enamored of this newly-found Suvarnabhumi, stayed put.

But all that changed around 14,000 years ago when rapidly melting ice unleashed cataclysmic floods, and maybe even tsunamis, which inundated many parts of the world. Large swaths of the low-lying coasts of Sundaland were especially badly battered and permanently submerged due to it.

Subsequently, two more massive flooding events took place around 11,500 years ago and 8,000 years ago, further swallowing up the elephantine landmass and eventually turning it into what it is today Peninsular Malaysia, the island of Borneo, the Indonesian Archipelago, and Singapore.

These bouts of cosmic angst unsurprisingly caused a mass exodus from the region. Genetic marker links indicate that migrant bands from Sundaland travelled to and colonised many parts of the world, including Eastern Europe, the Middle East, India, China, Korea, and New Guinea.

And when they did, they carried with them the seeds of civilisation that might have gone on to fertilise the great ancient cultures of the world, including Mesopotamia, Egypt, and India.

Dr Sangkot Marzuki of the Eijkman Institute in Jakarta encapsulates it well when he says: Southeast Asia is the place of origin from which modern man spread out to the rest of the world, after Africa.

Oppenheimer zeroes in on the location of the dispersion even further, saying that the genetic evidence for the spread of people from Southeast Asia round the Pacific Rim points to two Aboriginal areas, Sabah in northeast Borneo and the jungles of the Malay Peninsula.

In light of this groundbreaking scientific revelation, its about time we celebrated the Orang Asli and their ancient way of life, instead of looking at them as irrelevant relics of the past and relegating them to the sidelines of society.

Its about time we embraced and learned from these genetic and cultural time-capsules. After all, the Orang Asli provide a window into our forgotten past and are the proud custodians of tens of thousands of years of wisdom something few other cultures can lay claim to today.

And its definitely about time we invested a lot more money and dedicated a lot more academic firepower into studying the rich prehistory of our homeland. If we did, who knows what we would uncover next.

The views expressed are those of the author and do not necessarily reflect those of FMT.

Is Malaysia the cradle of civilisation? | Free Malaysia Today - Free Malaysia Today

Recommendation and review posted by Bethany Smith

PCOS and Endometriosis: How to spot the signs – The Indian Express

By: Lifestyle Desk | New Delhi | Updated: September 19, 2020 12:36:00 pmPCOS is so common in women intheir 20s that every 1 in 5 women go through it, while endometriosis is diagnosed in women, who are inbetween their 30s and 40s, said the expert. (Photo: Getty Images/Thinkstock)

Women often end up ignoring their health, and this can sometimes lead to serious issues like a reproductive disorder. It has been seen that health conditions like PCOS (Polycystic Ovarian Syndrome) and endometriosis are often gone undiagnosed as women feel that certain symptoms are variations of a normal menstrual cycle. PCOS is so common in women in their 20s that every 1 in 5 women go through it, while endometriosis is diagnosed in women, who are in between their 30s and 40s, said Dr Sandeep Chadha, consultant obstetrician and gynecologist, Motherhood Hospital, Noida.

Here are some differences and similarities between the two, and when its time to visit your doctor:

What is PCOS?

PCOS is a common hormonal disorder in women in which ovaries produce too many male hormones resulting in irregular or absent menstrual periods, weight gain, hair growth in unusual places like your face, neck, or abdomen, thinning hair on your scalp, acne on your face, chest, or back, and infertility issues.

But with the changing times, there has been difficulty in diagnosis of the condition. Experts suggest that they have been seeing many such women, who do not have all the classic symptoms but they still have been diagnosed with PCOS. While the cause of PCOS is still unclear, but genetics are thought to play a role and high levels of insulin and androgens exacerbate the problem. Excess insulin, which can lead to weight gain, is thought to boost androgen production in the ovaries. So, you are more prone to developing this disorder if you have a family history of PCOS, obesity or diabetes, she told

What is endometriosis?

Endometriosis is a condition in which the lining of the uterus, known as endometrium, grows outside the uterus or on other areas such as the ovaries, the outer surface of the uterus, the fallopian tubes, the vagina, the cervix, or even on the bladder or rectum. If a woman has the condition, she will have immensely painful periods with pelvic and lower back pain, pain during or after intercourse, pain while using the bathroom, excessive bleeding, digestive problems, and infertility are also common symptoms.

With a typical menstrual cycle, your endometrium thickens, breaks down, bleeds, and exits your body through the uterus each month. Like PCOS, endometriosis can be difficult to diagnose. Endometriosis is also challenging to diagnose because some women will have no symptoms, and other women who have all of the symptoms above may not necessarily have endometriosis. The exact reason behind endometriosis is also unknown. There are several theories, but none explain all aspects of the disorder, she explained.

Can you have both?

Unfortunately, you can have both, said the expert. She added that many mix-and-match possibilities can present themselves in women suffering from both, but the most common overlapping symptom is infertility.

ALSO READ | Count on these handy tips to prevent and manage polycystic ovarian syndrome

The regularity of your menstrual cycle and hormone testing can help differentiate between the two conditions. It is more common to see endometriosis present in women with regular cycles. However, if a patient with PCOS reports significant pelvic pain, this raises the possibility of another condition being present with PCOS, such as uterine fibroids or endometriosis, since PCOS does not cause pain during periods, she said.

However, any time if you experience especially painful or irregular cycles, notice abnormal hair growth, or struggle with infertility, then its time to visit your doctor.

What you can do

There are no known cures for PCOS or endometriosis, but both are treatable and the symptoms can be managed once correctly diagnosed. PCOS can be managed through hormonal birth control pills, which can help level hormones and therefore regulate periods. If youre trying to get pregnant and cant take birth control, then a doctor suggests some hormone therapy medications. For endometriosis, you can take an extended-cycle pill, which means you have a few periods or eliminating your period completely. A hormonal intrauterine device (IUD) is another option. It can be inserted to help reduce pain and bleeding. Surgery for endometriosis may improve your chances of pregnancy, depending on how extensive the condition has become, she said.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read the original post:
PCOS and Endometriosis: How to spot the signs - The Indian Express

Recommendation and review posted by Bethany Smith

Should I take an at-home Covid-19 test to hang out with friends? – Quartz

Theoretically, if everyone in a group tests negative for SARS-CoV-2, they could all safely meet up indoors with no masks or physical distancing. Yet with ongoing shortages of federal and state-provided testing in some areas, plus significant lag times to get results, its been hard for Americans to successfully carry out these plans.

Enter capitalism. The US Food and Drug Administration has granted emergency use authorization to several at-home Covid-19 tests developed by companies like LabCorp, Quest, and Everlywell. These tests offer nearly everyone the ability to collect a nasal swab sample from the convenience of their couch, and theyve become a popular option for those who want to try to regain a semblance of normalcy. But its important to remember that negative test result cant eliminate transmission risk entirely. Together with other risk-mitigation strategies, they simply make some lower risk hangouts possible.

As healthcare efficiencies go, at-home tests are hard to beat. Customers take a quick survey to gauge whether they may have Covid-19, even if theyre asymptomatic. If approved, they receive priority-shipped collection containers for nasal swabs, cold packs, and expedited return shipping labels. Collecting a nasal sample involves a cotton swab at the base of the nostril, and voila! Ship it back and get results in just a few days.

LabCorp is one of the two major Covid-19 testing companies used by doctors offices and other testing sites; Pixel is its consumer-facing brand. Tests by Pixel use the same polymerase chain reaction to look for SARS-CoV-2 genetic material as the test someone would receive in a hospital; essentially, the packaging is flashier and more consumer-friendly.

LabCorp created Pixel in November 2018, and allowed users to order at-home tests for things like vitamin deficiencies and basic assessments of kidney and liver functions. In early April, Pixel launched a Covid-19 test that was intended at first for only symptomatic healthcare professionals and other first responders. By May, the company had expanded its criteria: Anyone who believed they had been exposedmeaning they were in a large crowd where maintaining distancing wasnt possible, or they had been around someone who was sickcould get a test.

Other companies have since jumped in on the action, including Quest, another major testing company, Everlywell, which specializes in consumer-initiated genetic testing, and Lets Get Checked. Their tests cost between $100 and $130, and some, like LabCorps, can be covered by federal and private insurance. Some of that cost goes into testing and shipping, and a small portion goes to paying for an independent physician to review the consumers eligibility. Each test has a results turnaround time of a few days, making them seem perfect to head off any risks at planned gatherings. But are they enough?

Unfortunately, yeseven if you all get tested ahead of time.

[Covid-19 tests are] only positive during a very narrow window, says Michael Hochman, a physician at the Keck School of Medicine at the University of Southern California. SARS-CoV-2 takes a median of five days to make its presence known in the body; sometimes, it can take up to two weeks. If a person were to take a Covid-19 test too soon after being exposed, theyd get a false negative.

A review from researchers at Johns Hopkins University found that over the four days of infection before a person typically starts showing symptoms (on day five), the probability of a false negative was 100% on day one and 67% on day four. Three days after the onset of symptoms, there was still a 20% chance theyd be incorrectly told they didnt have the virus.

If someone showing no symptoms gets a Covid-19 test and its negative, thats not particularly reassuring, says Hochman. We should all the time act under the assumption that we are an asymptomatic carrier and that everyone around us is, too.

That doesnt mean you should stay home alone. Rather, its all about finding ways to mitigate your riskand the first step there is realizing that a truly zero-risk situation doesnt exist.

First, be smart about the kinds of activities you engage in. Spending time outdoors is ideal; hanging out indoors with masks on for short periods of time is also lower risk, and probably safe to do. Ditto sharing a car with the windows down. As always, you should avoid seeing someone who is sick indoors, especially without a mask.

Finally, consider who is in your group, and who you all may be seeing afterward. If you or those youre planning to travel with are at risk for developing a severe case of Covid-19, consider rethinking your plans. It would also be wise to abide by the 14-day quarantine once youre back from wherever you go. And above all, its still important to make sure everyone in the group is comfortable taking on those risks, and understands them.

Read more:
Should I take an at-home Covid-19 test to hang out with friends? - Quartz

Recommendation and review posted by Bethany Smith

Prenatal and New-born Genetic Testing Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2024 – The Research Process

Latest updates on Prenatal and New-born Genetic Testing market, a comprehensive study enumerating the latest price trends and pivotal drivers rendering a positive impact on the industry landscape. Further, the report is inclusive of the competitive terrain of this vertical in addition to the market share analysis and the contribution of the prominent contenders toward the overall industry.

Technological advancement and several benefits associated with infant genetic testing will be major driver of the prenatal and new-born genetic testing market. Introduction of prenatal testing has led to substantial amount of increase in adoption rate of new testing technologies such as non-invasive prenatal testing (NIPT) for detection of sub chromosomal abnormalities, single-gene disorders and aneuploidy in North America region. Inclination towards minimally invasive infant genetic testing along with demand for early detection of birth defects will one of the major reason for market growth.

Rising number of consanguineous relations in the developing countries of Asia and Middle East will foster growth opportunities for prenatal and newborn genetic testing market. The consanguineous relations are responsible for births of infants with defects and chromosomal abnormalities. Consequent, the increase in cases of live births diagnosed with birth defects will directly impact the growth of prenatal and new-born genetic testing market.

Request Sample Copy of this Report @

Prenatal and New-born Genetic Testing Market will exceed USD 7 billion by 2024; as per a new research report.

Request Sample Copy of this Report @

However, lack of infrastructure and skilled labor in the low and middle income countries will impede the parental and newborn genetic testing market growth. Moreover, ethical issues associated with prenatal and newborn testing coupled with incidences of false test results will further hamper industry growth.

Screening technology holds majority of market share in the year 2017 owing to increasing number of screening procedures of pregnant women while delivery. The rise in awareness among the families regarding genetic birth defects and early detection of genetic disorder will augment the segment growth in the near future.

Increasing prevalence of birth defects among the European population is one of the major reason for rising infant mortality. The necessary government initiatives in order to conduct prenatal and new-born genetic tests to diagnose the birth defects will increase the number of infant screening programs giving rise to market growth opportunities.

Downs Syndrome recorded largest market share in the prenatal and newborn genetic testing market due to increasing in number of births diagnosed with Downs syndrome. The rise in incidences of women getting married at later stage of life is leading to increasing births with Downs Syndrome. These factors will further support the segment growth over the forecast timeframe.

Hospitals hold the majority of market share owing to increasing number of births in hospitals. Hospitals are aided by the government and provide the facilities require for the newborn screening. The increase in number of screening programs in hospitals provides significant scope for the market growth.

Major Highlights from Table of contents are listed below for quick lookup into Prenatal and New-born Genetic Testing Market report

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Prenatal and New-born Genetic Testing Industry Insights

Chapter 4. Company Profiles

Request Customization on This Report @

Read more:
Prenatal and New-born Genetic Testing Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2024 - The Research Process

Recommendation and review posted by Bethany Smith

Cardiovascular Genetic Testing Market to Witness High Growth in Near Future and Competitive Analysis – The Daily Chronicle

Data Bridge Market Research has recently published the Global research Report Titled Cardiovascular Genetic Testing Market. The study provides an overview of current statistics and future predictions of the Global Cardiovascular Genetic Testing Market. The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Cardiovascular genetic testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 4.01 billion by 2027 growing at a CAGR of 13.40% in the above-mentioned forecast period. An extensive array of employment of genetic experimentation in inherent disorders and oncology will prove advantageous for genetic testing business germination in the coming years.

FREE Sample Copy of Research Report Click Here:

The Global Cardiovascular Genetic Testing Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Cardiovascular Genetic Testing market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Cardiovascular Genetic Testing Market in each region. Various methodological tools are used to analyze the growth of the worldwide Cardiovascular Genetic Testing market.

Top Key Vendors Covered in the report:

Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, QIAGEN, Pathway Genomics, Pacific Biosciences of California, Inc, Natera, Inc., Myriad Genetics, Inc., ICON plc, Laboratory Corporation of America Luminex Corporation, IntegraGen., HTG Molecular Diagnostics, Inc. , Genomic Health, Inc., Admera Health, deCODE genetics among other domestic and global players.

Regions included:

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

How Does This Market Insights Help?

Key Pointers Covered in the Cardiovascular Genetic Testing Market Industry Trends and Forecast to 2026

Why choose us:

A complete value chain of the global Cardiovascular Genetic Testing market is presented in the research report. It is associated with the review of the downstream and upstream components of the Cardiovascular Genetic Testing Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Cardiovascular Genetic Testing market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Cardiovascular Genetic Testing market.

Get Table Of Contents of This Premium Research For Free:


Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation



Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

For More Information or Query or Customization Before Buying, Click Here:

Customization of the Report

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thanks for reading this article you can also get individual chapter wise section or region wise report versions like North America, Europe, MEA, or Asia Pacific.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates


US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


View original post here:
Cardiovascular Genetic Testing Market to Witness High Growth in Near Future and Competitive Analysis - The Daily Chronicle

Recommendation and review posted by Bethany Smith

Direct-To-Consumer (DTC) Genetic Testing Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2028 – The Research Process

Latest updates on Direct-To-Consumer (DTC) Genetic Testing market, a comprehensive study enumerating the latest price trends and pivotal drivers rendering a positive impact on the industry landscape. Further, the report is inclusive of the competitive terrain of this vertical in addition to the market share analysis and the contribution of the prominent contenders toward the overall industry.

Consumers send the company a DNA sample like urine or saliva and collect their results directly from a written report or from a secure website. DTC genetic testing further provides access to people for their genetic information without the need for involving any health insurance company or a healthcare provider in the process.

Not all DTC tests are genetic tests, some are helpful in measuring other things like levels of toxins in urine, or levels of proteins in the human body and types of bacteria flora usually referred as microbiome.

Request Sample Copy of this Report @

Direct-to-consumer genetic testing market is anticipated to record a substantial growth rate over the coming years due to ongoing technological advancements. Direct-to-consumer genetic testing differs from typical genetic testing. These genetic tests are marketed directly to consumers through the medium of print advertisements, internet, or television, and can be bought in stores or online.

Request Sample Copy of this Report @

DTC genetic testing, home DNA testing, direct-access genetic testing, and at-home genetic testing are other names for direct-to-consumer genetic testing.

The direct-to-consumer genetic testing market is bifurcated in terms of test type, technology, distribution channel, and regional landscape.

Numerous companies are now offering DTC genetic tests for several purposes. The most common tests use genetic deviations to make estimates about health, give information regarding common traits, and also offer clues about an individual's ancestry. There is a rise in a number of companies providing DTC testing together with the range of health conditions and traits covered by these tests.

With respect to test type, the market is classified into predictive testing, nutrigenomic testing, ancestry, and relationship testing, carrier testing, and others. Among these, carrier testing is set to observe around 14% CAGR between 2020 to 2028, owing to the growing cases of rare genetic diseases that is affecting millions of people globally.

Based on technology, the market is segmented into whole genome sequencing (WGS), single nucleotide polymorphism (SNP) chips, and targeted analysis. Among these, SNP chips held around 50% market share, owing to the technology's efficacy and cost-effectiveness.

Major Highlights from Table of contents are listed below for quick lookup into Direct-To-Consumer (DTC) Genetic Testing Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Direct-To-Consumer (DTC) Genetic Testing industryInsights

Request Customization on This Report @

The rest is here:
Direct-To-Consumer (DTC) Genetic Testing Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2028 - The Research Process

Recommendation and review posted by Bethany Smith

Mother and daughter fighting breast cancer together embrace virtual support in time of COVID-19 – Wink News


Going through cancer is never easy and the pandemic is making a difficult time even harder.

For Paige Haddy, her journey with cancer hasnt happened alone. She and her mother have been side-by-side since day one.

She was just getting a simple, annual, routine mammogram actually, and they discovered the mass at that time, she said.

Genetic testing revealed both women had the BRCA02 mutation, putting them at a greater risk of developing breast cancer more than once.

Their best bet double mastectomies. Haddy delayed her surgery so she and her mom could lean on each other during their recoveries.

I had flown out previously for her five breast surgeries, she said. She was here for my initial surgery, my prophylactic double mastectomy in December.

But that plan came together pre-pandemic. Not only did Haddys follow-up surgery get pushed back due to COVID-19 concerns, but when the time came, her mom couldnt come in.

Going through this last one without her was very difficult to get through, Haddy said.

You cant have a big group of loved ones coming with you to the hospitals or the clinics, and thats tough, said Megan Wessel with the American Cancer Society. What we can do is be there for them afterwards.

Wessel says the non-profit can connect cancer patients to new support systems to help get them through the pandemic and beyond.

We can match up a breast cancer patient with a woman who has been through breast cancer and that has a similar experience with them, she said. We also have a cancer survivors network thats online.

Its a new normal Haddy, the Pink Bra Ambassador for the American Cancer Society Southwest Florida, has had to adjust to, and one she fully embraces.

Theres a community there to help and I know I found it just such a key component to my healing process, she said.

Aside from the American Cancer Society, there are several breast cancer support groups in Southwest Florida. For more information on those groups, take a look at the links below:

Read more:
Mother and daughter fighting breast cancer together embrace virtual support in time of COVID-19 - Wink News

Recommendation and review posted by Bethany Smith

Preimplantation Genetic Testing Market to Witness Exponential Growth by 2020-2027 | Leading Players Illumina, Thermo Fisher Scientific, Agilent…

Fort Collins, Colorado The report on the Preimplantation Genetic Testing Market provides an in-depth assessment of the Preimplantation Genetic Testing market including technological advancements, market drivers, challenges, current and emerging trends, opportunities, threats, risks, strategic developments, product advancements, and other key features. The report covers market size estimation, share, growth rate, global position, and regional analysis of the market. The report also covers forecast estimations for investments in the Preimplantation Genetic Testing industry from 2020 to 2027.

The report is furnished with the latest market dynamics and economic scenario in regards to the COVID-19 pandemic. The pandemic has brought about drastic changes in the economy of the world and has affected several key segments and growth opportunities. The report provides an in-depth impact analysis of the pandemic on the market to better understand the latest changes in the market and gain a futuristic outlook on a post-COVID-19 scenario.

Global Preimplantation Genetic Testing Market was valued at 401.49 million in 2019 and is projected to reach USD796.89 million by 2027, growing at a CAGR of 9.65% from 2020 to 2027.

Get a sample of the report @

The report provides an in-depth analysis of the key developments and innovations of the market, such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report provides a comprehensive overview of the regional growth of each market player.

Additionally, the report provides details about the revenue estimation, financial standings, capacity, import/export, supply and demand ratio, production and consumption trends, CAGR, market share, market growth dynamics, and market segmentation analysis.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Furthermore, the report utilizes advanced analytical tools such as SWOT analysis and Porters Five Forces Analysis to analyze key industry players and their market scope. The report also provides feasibility analysis and investment return analysis. It also provides strategic recommendations to formulate investment strategies and provides insights for new entrants.

Request a discount on the report @

The report is designed with an aim to assist the reader in taking beneficial data and making fruitful decisions to accelerate their businesses. The report provides an examination of the economic scenario, along with benefits, limitations, supply, production, demands, and development rate of the market.

1.Preimplantation Genetic Testing Market, By Technology:

Next-Generation Sequencing Polymerase Chain Reaction Fluorescence in Situ Hybridization Comparative Genomic Hybridization Single-Nucleotide Polymorphism

2.Preimplantation Genetic Testing Market, By Procedure Type:

Preimplantation Genetic Screening Preimplantation Genetic Diagnosis

3.Preimplantation Genetic Testing Market, By Application:

Aneuploidy Structural Chromosomal Abnormalities Translocations Deletions Duplications Inversions Single Gene Disorders X-Linked Disorders HLA Typing Gender Identification

4.Preimplantation Genetic Testing Market, By Products And Services:

Reagents and Consumables Instruments Software and Services

5.Preimplantation Genetic Testing Market, By End User:

Maternity Centers & Fertility Clinics Hospitals, Diagnostic Labs, and Service Providers Research Laboratories & Academic Institutes

Request customization of the report @

Regional Analysis of the Market:

For a better understanding of the global Preimplantation Genetic Testing market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread acrossNorth America, Europe, Latin America, Asia-Pacific, and Middle East & Africa.Each region is analyzed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market.

Benefits of the Global Preimplantation Genetic Testing Report:

To learn more about the report, visit @

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390


Go here to read the rest:
Preimplantation Genetic Testing Market to Witness Exponential Growth by 2020-2027 | Leading Players Illumina, Thermo Fisher Scientific, Agilent...

Recommendation and review posted by Bethany Smith

Pharmacogenetic Testing: Does it Improve Therapy in Patients With MDD? – Neurology Advisor

Major depressive disorder (MDD) is a common mental disorder that affects more than 264 million people worldwide and is a leading cause of disability, including death by suicide.1 MDD is a complicated disorder that involves the interaction of social, psychological, and biological factors.1 MDD can prevent patients from living healthy, productive lives and can complicate treatment of other comorbid conditions.1

Although MDD commonly is encountered in primary care settings, its treatment has become integrated into all fields of medicine due to its high prevalence. Cognitive behavioral therapy, interpersonal psychotherapy, and antidepressants, such as selective serotonin reuptake inhibitors and tricyclic antidepressants, are the mainstays of MDD treatment.1

Prescribing an antidepressant may be simple, but that does not make it easy. Efficacy and tolerability of antidepressants vary among patients, which can make it challenging to relieve patients symptoms.2 Although no genes have been associated with depression,3 several genetic variants may help clinicians predict how patients with MDD will metabolize antidepressants.4 Performing genetic testing of patients with MDD and matching patients with an antidepressant class based on identification of genetic variants that convey sensitivity to particular antidepressants could improve response to drug therapy in patients with MDD.5

The process of selecting an antidepressant should take into account cost, tolerability, adverse effect profiles, and patient preferences.2 When evaluating treatment options for patients with MDD, the current standard of care is to initiate an antidepressant at a starting dose and reassess effectiveness within 2 to 4 weeks, with adjustments to monitoring frequency dependent on the patients suicide and self-harm risk, comorbid conditions, age, and concomitant medication use.2

Several metrics are used to determine whether a selected antidepressant is working:

Clinicians can mitigate adverse effects by decreasing the dosage or switching to a different class of antidepressant. However, several weeks are needed after each change in drug or dose alteration to truly assess response. Finding and settling on a drug that produces a response with minimal adverse effects can take months. During the trial period, patients may become frustrated with the process and stop therapy and/or may be at increased risk for suicide or self-harm.

The study of drug metabolism in patients with MDD is a growing area of interest.3-5 A management approach incorporating pharmacogenetic testing in combination with clinical judgment may be superior to the standard trial and error method for finding an effective antidepressant regimen and could improve patient outcomes.5

Genome-wide association studies are used to identify single nucleotide polymorphisms (SNPs) in genes related to a particular disease or drug metabolism.6 Several laboratory testing companies offer pharmacogenetic panels to evaluate metabolism of drugs used to treat MDD.3 The FDA also has approved direct-to-consumer genetic testing panels (eg, 23andMe), which are widely available to the public without a health care providers prescription.7 A concern with these latter tests is that the results of these tests are reported directly from the company to the patient; thus, the patient decides whether or not to present the information to his or her health care provider. Many pharmacogenetic testing panels also include genes that have shown correlations with the pathogenesis of MDD, despite the lack of clinical research replicating the role of these genes in the disorder.3

This article originally appeared on Clinical Advisor

Here is the original post:
Pharmacogenetic Testing: Does it Improve Therapy in Patients With MDD? - Neurology Advisor

Recommendation and review posted by Bethany Smith

Drug Company Touts Anti-Inflammatory Drug’s Role In Shortening COVID Recovery – Kaiser Health News

Eli Lilly said it planned to discuss with regulators the possible emergency use of baricitinib for hospitalized patients. Other news is about early research on an antibody that might neutralize COVID and how the virus controls the brain, as well.

AP:Anti-Inflammatory Drug May Shorten COVID-19 Recovery TimeA drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day. Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The study tested baricitinib, a pill that Indianapolis-based Lilly already sells as Olumiant to treat rheumatoid arthritis. (Marchione, 9/14)

The Hill:Drugmaker Says Anti-Inflamatory Medicine May Shorten COVID-19 Recovery TimeThe use of Baricitinib, arheumatoidarthritis drug from Eli Lilly, led to a one-day reduction in recovery time for patients when combined with Remdesivir compared to patients who only took Remdesivir, according to a trial. The finding was statistically significant, Eli Lilly said in a statement. The company did not release the full results of the study but stated the National Institute of Allergy and Infectious Diseases (NIAID) is expected to publish full results in peer-review studies and that additional analyses are ongoing to understand clinical outcome data, including safety and morbidity data. (9/14)

In other scientific developments

Fox News:University Of Pittsburgh Scientists Discover Antibody That 'neutralizes' Virus That Causes CoronavirusScientists at the University of Pittsburgh School of Medicine have isolated the smallest biological molecule that completely and specifically neutralizes SARS-CoV-2, the virus that causes the novel coronavirus. The antibody component is 10 times smaller than a full-sized antibody, and has been used to create the drug Ab8, shared in the report published by the researchers in the journal Cell on Monday. The drug is seen as a potential preventative against SARS-CoV-2. (Deabler, 9/14)

Fox News:Coronavirus Can 'Hijack' Brain Cells To Replicate Itself, Yale Researchers DiscoverThe coronavirus can affect the brain and hijack brain cells to replicate itself, Yale University researchers have discovered. A new study from Yale University, on BioRXiv, which is awaiting peer review, found that the brain is another organ susceptible to an attack by the novel coronavirus. (McGorry, 9/14)

Stat:23andMe Research Finds Possible Link Between Blood Type And Covid-19A forthcoming study from genetic testing giant 23andMe shows that a persons genetic code could be connected to how likely they are to catch Covid-19 and how severely they could experience the disease if they catch it. Its an important confirmation of earlier work on the subject. People whose blood group is O seemed to test positive for Covid-19 less often than expected when compared to people with any other blood group, according to 23andMes data; people who tested positive and had a specific variant of another gene also seemed to be more likely to have serious respiratory symptoms. (Sheridan, 9/14)

Read more:
Drug Company Touts Anti-Inflammatory Drug's Role In Shortening COVID Recovery - Kaiser Health News

Recommendation and review posted by Bethany Smith

BCS Announces Partnership With 2nd.MD to Improve Member Healthcare Cost, Quality, and Outcomes – PRNewswire

CHICAGO, Sept. 16, 2020 /PRNewswire/ -- BCS Financial (BCS) announces today it has partnered with 2nd.MD to provide top-tier medical navigation, expert consultation, and personalized second opinions to four million policyholders. Under the agreement, members covered under BCS Stop Loss and Excess of Loss policies can work with highly skilled, experienced nurses to help them navigate diagnoses, virtually connect with elite doctors who specialize in their specific condition, and receive assistance finding a local doctor or specialist in their area at no cost to them.

As the number one reinsurer of Blue Cross Blue Shield plans, BCS offers a wide range of products and services to help insurance carriers and their members navigate healthcare costs, particularly those exceeding $500,000 annually. The partnership is one of several features included in BCS Financial's Risk Navigator solutions, a highly predictive and actionable approach to managing claims risk.

"Second opinions can play a vital part in ensuring healthcare costs are not wasted on unnecessary or incorrect care," said Peter Costello, presidentand chief executive officer, BCS Financial. "BCS is committed to helping our policyholders and their members manage their risks while improving healthcare outcomes."

Members see direct benefit from the second-opinion consultation. "Members facing a complex diagnosis, surgeryor healthcare decision often find it difficult to navigate the healthcare system and manage costs," said Chris Kurtenbach, vice president, Services & Operations, BCS Financial. "With this partnership, we can help members get the appropriate care they need by connecting them with board-certified, elite specialists from top medical institutions, and reducing their costs along the way."

In many cases, the second opinion can change the treatment trajectory 85% of 2nd.MD's consultations result in improved treatment plans, 35% lead to alternative diagnoses, and nearly 30% of surgery consults result in surgery cancellation.

This is an especially important service as the market for gene therapy and cellular immunotherapy continues to ramp up. An estimated 50-75 therapies will be approved for the U.S. market by 2030, with costs for cellular immunotherapies averaging around $400,000, and gene therapy costs estimated in the $2-$4 million range. For those with complex cancers, rare or orphan conditions, and aggressive recommendations, access to top specialists can make all the difference.

"Better care and outcomes for members is always our priority," said Costello. "This partnership is just one of the ways we are delivering value to our Blue Cross and Blue Shield partners and their members by helping them continue to manage healthcare costs and quality."

This service is currently available to members covered by BCS Stop Loss and Excess of Loss policies.

About BCS Financial Corporation (BCS)

BCS Financial Corporation has more than 70 years of experience delivering a wide-range of insurance and financial solutions for Blue Cross and Blue Shield organizations nationwide. Through its subsidiaries, BCS Insurance Company and 4 Ever Life Insurance Company, BCS is licensed in all 50 states and is rated A- (Excellent) by A.M. Best. BCS Financial is headquartered in Oakbrook Terrace, Illinois. Learn more at

About 2nd.MD

2nd.MD offers medical certainty by connecting you with board-certified, leading specialists from across the country for an expert second opinion via video or phone within three to five days, from the comfort of your own home. From the minute you reach out, 2nd.MD's Care Team of nurses will put you at the center of your medical care by coordinating all the details. This includes understanding your health goals, gathering all of your medical records, and connecting you with a doctor who specializes in your specific medical condition, so that you can focus on what matters most getting the best care possible. No travel. No hassle. No cost. If you haven't used 2nd.MD before, it can be life-changing. In fact, 98% of people who use 2nd.MD recommend it to their friends and family.

For more information, please contact Nathan Post at 630-472-7860.

SOURCE BCS Financial Corporation

BCS Announces Partnership With 2nd.MD to Improve Member Healthcare Cost, Quality, and Outcomes - PRNewswire

Recommendation and review posted by Bethany Smith

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics – Business Wire

IRVINE, Calif. & BOSTON--(BUSINESS WIRE)--Novus Therapeutics, Inc. (Novus) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (Anelixis), a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. Concurrent with the acquisition of Anelixis, Novus entered into a definitive agreement for the sale of non-voting convertible preferred stock (the Preferred Stock) in a private placement to a group of institutional accredited investors led by BVF Partners L.P., with participation from Cormorant Asset Management, Ecor1 Capital, Logos Capital, Fidelity Management and Research Company, Adage Capital Partners L.P., Woodline Partners LP, Ridgeback Capital, Janus Henderson Investors, and Samsara BioCapital, as well as additional investors. The private placement is expected to result in gross proceeds to Novus of approximately $108 million before deducting placement agent and other offering expenses. The proceeds from the private placement will be used to fund the Companys operations, including to advance Phase 2 clinical trials of AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40L, in renal transplantation, islet cell transplantation, autoimmune nephritis, and amyotrophic lateral sclerosis (ALS).

We are excited about AT-1501 and the potential to develop and commercialize the next generation anti-CD40L antibody, a well-validated target with broad therapeutic possibilities, said Keith A. Katkin, Chairman of the Board of Directors of Novus. After exploring a range of strategic options to maximize shareholder value, we believe this acquisition represents the greatest value creation opportunity for Novus stockholders, and we are confident that we have the management and scientific leadership team to fully realize this opportunity for patients in need of new treatment options.

Leadership & Organization

In addition to the strategic acquisition and private placement, Novus announced its Board of Directors has previously appointed David-Alexandre DA C. Gros, M.D. to serve as Chief Executive Officer and Director. Dr. Gros joins Novus from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Director. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith, Inc., and in healthcare consulting at McKinsey & Company. Dr. Gros earned a Doctor of Medicine from Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.

I am both thrilled and humbled to join the Novus management team and Board during this new phase of the companys evolution, as we prepare to initiate multiple Phase 2 trials for AT-1501 said Dr. Gros. Through this acquisition and financing, we now have the scientific, organizational and financial resources to build upon a deep historical understanding of the CD40/CD40L pathway, as well as Anelixis preclinical and Phase 1 data, to address the needs of people undergoing organ or cellular transplantation, or living with autoimmune and neurodegenerative diseases.

Joining Dr. Gros on the Novus management team and Board of Directors is Steven Perrin, Ph.D., Founder and Chief Executive Officer of Anelixis, who will take on the role of President and Chief Scientific Officer. Dr. Perrin brings 20 years of drug development experience to Novus, having held R&D positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. Over the past decade, Dr. Perrin has worked with the ALS Therapy Development Institute to develop the worlds largest ALS drug development program, bridging preclinical and clinical programs. Dr. Perrin received a Ph.D. in biochemistry from Boston University Medical Center, where he also started his career as Associate Professor of Medicine, and a Bachelor of Science from Boston College.

The activation of CD40/CD40L signaling is critical to mediating antibody and cellular inflammatory response. We are developing antibodies to inhibit the activation of this pathway with the hope of offering new treatment modalities for people living with conditions such as autoimmune nephritis and ALS, or those requiring a potentially life-saving transplant, said Dr. Perrin. I have dedicated my career to developing better medicines for these patients and their families, and I look forward to working with the team to advance these clinical programs.

Concurrent with the acquisition, former Anelixis Chairman of the Board Walter Ogier has been appointed to the Novus Board of Directors. Mr. Ogier has more than 30 years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies, and gene therapies. He has served in multiple CEO roles including Genetix Pharmaceuticals, Inc. (now bluebird bio, Inc.) and Acetylon Pharmaceuticals, Inc., which Celgene Corporation acquired in 2016. In addition to Novus, he serves as a director of Biothera Pharmaceuticals, Inc., Thetis Pharmaceuticals, LLC, and Nemucore Medical Innovations, Inc., and as Board advisor to Kodikaz Therapeutic Solutions, Inc., and ME Therapeutics, Inc.

Novus Board members will also include Keith A. Katkin, Chairman of the Board; Gary A. Lyons; and John S. McBride. The company will continue to maintain its executive offices in Irvine, Calif. and will have research and development facilities in Boston, Mass.

About the Transactions

The acquisition of Anelixis was structured as a stock-for-stock transaction whereby all of Anelixis outstanding equity interests were exchanged in a merger for a combination of shares of Novus common stock and shares of Preferred Stock. Concurrently with the acquisition of Anelixis, Novus entered into definitive agreements for a PIPE investment with existing and new investors to raise approximately $108 million in which the investors will be issued shares of Preferred Stock at a price of approximately $500 per share (or, $0.50 per share on an as-converted-to-common basis). The PIPE offering is expected to close on September 14, 2020. Subject to stockholder approval, each share of Preferred Stock will, at the option of the holder, be convertible into 1,000 shares of common stock, subject to certain beneficial ownership limitations set by each holder. The acquisition was approved by the Board of Directors of Novus and the equity holders of Anelixis.

Ladenburg Thalmann & Co. Inc. is serving as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is serving as legal counsel to Novus. Goodwin Procter LLP is serving as legal counsel to Anelixis. SVB Leerink is serving as financial advisor and lead placement agent for the private placement, and Noble Life Science Partners, a division of Noble Capital Markets, Inc., is acting as co-placement agent.

Additional details are available in an updated corporate presentation that can be found online at

Webcast Details

Novus will host an audio webcast on Tuesday, September 15, 2020, at 8:30 a.m. EDT to discuss the acquisition. The live audio webcast will be accessible through a direct link and the investor section of To access via phone, please dial (833) 614-1390 (toll-free) or (914) 987-7111 (international) and provide the conference ID 4046285. Please visit the investor section of the Novus website at for the archived webcast and for more information on the acquisition.

About AT-1501

AT-1501 is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation. In a Phase 1 safety study of healthy volunteers and patients with ALS, AT-1501 was well tolerated at all doses tested.

About Novus Therapeutics

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, Calif. For more information, please visit the companys website at

Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.

Notice of Issuance of Inducement Grants

Pursuant to their employment agreements, Drs. Gros and Perrin have been awarded options to purchase a total of 18,279 and 7,857 shares of Preferred Stock, respectively, subject to time-based vesting (the "Inducement Grants"). The Inducement Grants have an exercise price of $500 per share of Preferred Stock, which is equal to the price at which the Preferred Stock is being offered and sold in the PIPE financing and represents (on an as-converted basis) a premium of approximately 30% over the last reported closing price of the Novus common stock prior to grant. The Inducement Grants have been approved by the Novus Board of Directors and the Compensation Committee of the Board of Directors. The Inducement Grants will be issued outside of the Company's stockholder-approved equity incentive plans as an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4).

Forward-Looking Statements

This press release contains forward-looking statements that involves substantial risks and uncertainties. Any statements about the companys future expectations, plans and prospects, including statements about its strategy, future operations, development of its product candidates, and other statements containing the words believes, anticipates, plans, expects, estimates, intends, predicts, projects, targets, looks forward, could, may, and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, although not all forward-looking statements include such identifying words. Forward-looking statements include, but are not limited to statements regarding: risks related to market conditions; expectations regarding the timing for the commencement of future clinical trials; expectations regarding the success of clinical trials; the rate and degree of market acceptance and clinical utility of the companys products; the companys estimates regarding expenses and cash runway; and the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the companys actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the SEC, which can be found at Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the rest here:
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics - Business Wire

Recommendation and review posted by Bethany Smith

Helixmith eyeing P3-3 clinical trials of gene therapy Engensis – Korea Biomedical Review

Helixmith said Wednesday that it has submitted a phase 3-3 extension study protocol of its gene therapy Engensis (VM202) for diabetic peripheral neuropathy (DPN), to the U.S. Food and Drug Administration.

The company set a one-year follow-up period to confirm the pain reduction and safety of VM202 in treating DPN. DPN is one of the most common complications of diabetic diseases. About 30 million Americans have diabetes, and 28.5 percent of them develop DPN. Among the DPN patients, 40 to 50 percent experience painful symptoms.

The study's primary endpoint is the average pain reduction effect measured and recorded in the pain diary over the last week of the sixth month from the first injection.

The study will be carried out with patients who had not taken Gabapentinoids, such as Pregabalin and Gabapentine, in 15 research laboratories across the U.S., including Northwestern University in Chicago.

"Existing painkillers for DPN patients are not a fundamental treatment for the disease as they only relieved pain while often accompanying serious side effects and high addiction," Helixmith CEO Kim Sun-young said. "We will try our best for the success of phase 3-3 clinical trials as well as the ongoing phase 3-2 study."

FDA recognized the clinical results of Engennsis and designated it as an advanced regenerative medicine advanced therapy (RMAT) in 2018, the company said. RMAT is a new system designed to speed up the development and approval of innovative regenerative therapies. It gives special privileges of the U.S. fast track and priority or accelerated screening.

See original here:
Helixmith eyeing P3-3 clinical trials of gene therapy Engensis - Korea Biomedical Review

Recommendation and review posted by Bethany Smith

GreenLight Biosciences Receives $3.3 Million Grant to Develop Sickle Cell Disease Cure Using mRNA Gene Therapy – PRNewswire

BOSTON, Sept. 15, 2020 /PRNewswire/ --GreenLight Bioscienceshas received a $3.3 million grant from the Bill & Melinda Gates Foundation to develop new mRNA-based gene therapies for Sickle Cell Disease and other global health challenges.

The funding will support GreenLight's research and testing of affordable therapies using the company's novel messenger RNA (mRNA) approach to gene editing. mRNA technology is already being used to develop vaccine candidates for infectious diseases, including the COVID-19 pandemic.

While initial research will focus on a cure for Sickle Cell Disease, GreenLight plans to develop a versatile gene editing platform to address a variety of diseases affecting underserved patient populations, such as treating HIV in developing countries.

Sickle Cell Disease is a group of inherited blood disorders in which red blood cells develop abnormally, causing pain and anemia. More than 4 million people currently suffer from the disease, with another 40+ million having the sickle cell trait, which can be passed on to future generations. The disease primarily targets people of African, Hispanic, or Middle Eastern descent. Current treatment regimens including blood transfusions and bone marrow transplants are costly, invasive, and impractical for treating large segments of affected patient populations.

"Funders are recognizing the potential of our innovative approach to gene editing that, in combination with our proprietary RNA manufacturing capability, has the potential to deliver accessible gene therapies and improve human health globally," said Marta Ortega-Valle, senior vice president of Human Health and Corporate Development at GreenLight Biosciences. "Finding a safe and effective therapy is critical, but equally important is the ability to produce it affordably for broader access. We are grateful for the Gates Foundation's support to advance novel gene editing approaches for populations in which those therapies are currently out of reach."

Gene editing therapies hold significant promise in the treatment of Sickle Cell Disease since it is a disorder caused by gene mutation. Using RNA as its core, GreenLight Biosciences is working to develop an in vivo gene therapy that could ultimately offer a cure to the disease.

Once the therapy candidate is validated and moves into clinical use, GreenLight Biosciences' biomanufacturing platform will accelerate production of affordable treatments at scale. "Manufacturing sufficient quantities of high-quality RNA at an accessible cost is critical for achieving the full potential of new therapies that aim to reach a global patient population. That capability does not yet exist in the market, but GreenLight's end-to-end, self-contained manufacturing platform aims to make that possible for all mRNA-based therapies and vaccines," Ortega-Valle added.

About GreenLight Biosciences, Inc.GreenLight is a bio-performance company with a unique, cell-free production platform that delivers high-performing RNA solutions to human, plant and animal challenges. GreenLight develops RNA products for plant and life science applications, and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, and plant protection. The cutting-edge, natural platform delivers higher-quality RNA at a lower cost and higher speed than was ever before possible. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world. For more information, visit

SOURCE GreenLight Biosciences

Originally posted here:
GreenLight Biosciences Receives $3.3 Million Grant to Develop Sickle Cell Disease Cure Using mRNA Gene Therapy - PRNewswire

Recommendation and review posted by Bethany Smith